March 10, 2015Diabetes Care
Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial
Why the study?
Does saxagliptin reduce the composite of cardiovascular mortality, myocardial infarction, or ischemic stroke in older patients with diabetes mellitus?
Population
16,492 individuals ≥40 years with diabetes mellitus, including 8,561 elderly and 2,330 very elderly…
Comparison
Saxagliptin 5 or 2.5 mg daily vs Placebo
Design
RCT, 1:1, double-blind
Follow-up
median 2.1 years
Authors
Discussion
Loading...
Member takes
Implication
Saxagliptin shows consistent cardiovascular safety across ages in diabetes; confirms similar effects in elderly versus younger patients.
Structured PICO
Does saxagliptin reduce the composite of cardiovascular mortality, myocardial infarction, or ischemic stroke in older patients with diabetes mellitus?
P
Population
16,492 individuals ≥40 years with diabetes mellitus (HbA1c ≥6.5% and ≤12.0%), including 8,561 elderly (≥65 years) and 2,330 very elderly (≥75 years) participants.
I
Intervention
Saxagliptin 5 or 2.5 mg daily
C
Comparator
Placebo
O
Outcome
Composite of cardiovascular mortality, myocardial infarction, or ischemic strokecomposite
Saxagliptin demonstrates a similar cardiovascular safety and glycemic efficacy profile in older versus younger patients with diabetes, while confirming an increased risk of heart failure hospitalization and hypoglycemia across all age groups.
Cite This Study
Leiter et al. (2015) studied this question.